Pricing Log in Create free account

Apimeds Pharmaceuticals US, Inc. (APUS) vs BioXcel Therapeutics, Inc. (BTAIQ)

Apimeds Pharmaceuticals US, Inc. and BioXcel Therapeutics, Inc. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $4.1M against $2.3M — 1.8× the size. Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −9,549.9%) and the lower return on invested capital (−16.0% vs 0.00%). Across the 12 metrics below, Apimeds Pharmaceuticals US, Inc. leads on 7 and BioXcel Therapeutics, Inc. on 5.

Valuation

Metric APUS BTAIQ Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S n/m 0.41 2.08
P/B 0.04 n/m 1.79
Price to free cash flow n/m n/m 16.29
EV/EBITDA n/m n/m 12.22
EV/Sales n/m 227.51 2.87
Earnings yield (1,394.72%) (37,900.00%) (15.94%)
Free cash flow yield (295.94%) (16,806.60%) 0.00%

Profitability

Metric APUS BTAIQ Drug Manufacturers Specialty & Generic median
Gross margin — 53.10% 53.51%
Operating margin 0.00% (6,054.72%) 0.00%
Net margin 0.00% (9,549.87%) (2.45%)
Free cash flow margin 0.00% (6,860.38%) 0.00%
Return on equity (100.13%) 63.52% (0.80%)
Return on assets (84.20%) (259.62%) (1.67%)
Return on invested capital (15.96%) 0.00% 0.00%

Growth

Metric APUS BTAIQ Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — (14.52%) 5.22%
EPS growth (last fiscal year) (205.56%) 75.63% 42.91%
Revenue growth, 5-year CAGR — — 7.24%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS BTAIQ Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 (0.90) 0.04
Current ratio 0.51 0.21 2.41
Net debt to EBITDA 0.38 (1.61) 1.01

Dividend

Metric APUS BTAIQ Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric APUS BTAIQ Drug Manufacturers Specialty & Generic median
Market cap 4.12m 2.31m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack